FN1 and cancer: While checkpoint blockade immunotherapy has significantly improved outcomes in certain advanced cancers,[8] its efficacy in PDAC remains limited.[9] This resistance stems from the ability of PDAC to hijack stromal components to create a favorable TME that promotes tumor growth and impedes immunotherapy.[6] The PDAC TME comprises cancer‐associated fibroblasts, immune cells, neurons, and an abundance of extracellular matrix (ECM) components, including collagen, fibronectin, and hyaluronic acid.